Quality Metrics & Performance

Quality measurement pressure is intensifying across Medicare payment channels: physicians in Congress are pushing a MIPS overhaul, while Clover’s MA Star Ratings litigation underscores how high-stakes quality scoring now directly affects bids, revenue, and market positioning for Medicare Advantage plans. At the same time, VBC stakeholders are broadening the definition of “performance” beyond traditional utilization and clinical measures—linking biosimilar adoption to provider performance in Medicare value-based payment models and expanding outcomes-based approaches in pharmacy, autism therapy, and CMS’s ACCESS Model—raising the bar for data infrastructure, attribution, and specialty-specific quality measurement. For ACOs, health systems, and payers, the week’s pattern is clear: quality metrics are becoming more financially consequential, more contested, and more dependent on analytics capabilities that can translate care management activity into measurable performance gains (biosimilars and Medicare VBP; [MIPS overhaul](https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSDVCRGFCLURCNDU3YVN4V3JFYWxnU2kzUnlOZl81UFo3bC14U1ozT18yRS12MHJibFdTOFFGOHIyRDZGbk9Ibl9ReDB3WXJkV3Q4alR0eE